Q32 Bio Inc

QTTB

Company Profile

  • Business description

    Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to effectively and safely restore healthy immune balance in patients with autoimmune & inflammatory diseases driven by pathological immune dysfunction. Q32 is advancing antibody-based therapeutic candidates designed to target two central pathways of adaptive & innate immunity. The adaptive immune system is largely composed of T- & B-cell mediated cellular & antibody responses, while the innate immune system is the body’s first line of defense employing leukocytes that are responsible for clearing pathogens and cellular debris and modulating T- & B-cell function. ADX-097, the lead product candidate from Q32’s complement inhibitor platform, is a humanized anti-C3d monoclonal antibody fusion protein.

  • Contact

    830 Winter Street
    WalthamMA02451
    USA

    T: +1 718 999-0232

    https://www.q32bio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    29

Stocks News & Analysis

stocks

Unconventional wisdom: Are dividends the answers?

As investors toil in complexity the obvious solution may be the right one.
stocks

Netflix: A business that’s nearly flawless

Streaming giant’s stellar results had areas of softness; currency tailwinds drive guidance raise.
stocks

Trump’s US dollar assault is fuelling CBA’s rise

A recent $1 billion investment in CBA by Texas based fund manager expresses concern for the outlook of the USD.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,934.3045.10-0.50%
CAC 407,834.5816.300.21%
DAX 4024,217.5078.43-0.32%
Dow JONES (US)44,901.92208.010.47%
FTSE 1009,120.3118.06-0.20%
HKSE25,388.35278.83-1.09%
NASDAQ21,108.3250.360.24%
Nikkei 22541,456.23370.11-0.88%
NZX 50 Index12,853.4648.330.38%
S&P 5006,388.6425.290.40%
S&P/ASX 2008,666.9042.50-0.49%
SSE Composite Index3,593.6612.07-0.33%

Market Movers